Acute and chronic cyclosporine A (CsA) nephrotoxicity are still relevant clinical problems in kidney transplantation. 1, 2 Sirolimus (SRL) is a non-nephrotoxic agent that blocks signal 3 in the three-signal model of T cell-mediated rejection by preventing cytokine receptors from activating the cell cycle. 3, 4 SRL immunosuppressive activity is mediated by the binding to a unique serine-threonine kinase mammalian target of rapamycin which plays a key role in cytokine-driven signals, protein synthesis, and T-cell expansion via G1-S cell cycle progression. 5 T-cell proliferation under SRL immunosuppression is also inhibited by the block of the interleukin-2 (IL-2)-mediated signal-transduction. 6 In the T cell-mediated rejection, T-helper (Th) lymphocytes play a critical role in either initiation and progression of allograft rejection. 7 CD4 þ alloreactive response differentiates into two distinct Th cell subsets, Th1 and Th2 cells, characterized by distinct cytokine patterns. 7, 8 Th1 response is defined by IL-2 and interferon-g (INFg) secretion, whereas IL-4, IL-5, IL-6, and IL-13 are released by Th2 cells that also promote B-cell maturation. The cytokine microenvironment dictates whether a Th0 lymphocyte will develop into a polarized Th1 or Th2 cell. 7 Among other cytokines secreted by monocyte and dendritic cells, IL-12 and IL-18 have a critical role in driving Th0 lymphocytes to Th1 polarization. 8, 9 Th1 cytokines have long been implicated in the acute rejection process. In fact, a release of Th1 cytokines IL-2 and IFNg has been reported in several gene expression studies in experimental 10 and human kidney transplantation at the time of allograft rejection. 11, 12 Heeger et al. 13 have demonstrated that the number of pretransplant IFNg-producing cells analyzed by an enzyme-linked immunosorbent spot (ELISPOT) assay correlates with the risk of post-transplantation rejection episodes. Recent studies have established that for measuring T-cell responses, the ELISPOT assay is more sensitive than a number of other techniques like enzymelinked immunosorbent assay, intracellular cytokine staining, or thymidine incorporation assays. 14 In spite of the potential relevance of these issues, few data are available on Th activity in immunosuppressed patients after solid organ transplantation. The aim of the present study was to compare Th subsets in kidney-transplanted patients treated with SRL-or CsA-based immunosuppressive regimens.
RESULTS
Patients enrolled into the study did not show signs of acute rejection at the time of inclusion and never before randomization. No severe bacterial, viral, or fungal infection occurred before inclusion in the study. Plasma creatinine levels were not significantly different in the rapamicine (RAPA group) (1.2670.47 mg/dl) when compared with CsA-1 (1.6670.52 mg/dl) and CsA-2 (1.5870.38 mg/dl) groups, respectively. Side effects associated with immunosuppression are summarized in Table 1 . Hypertrygliceridemia and hypercholesterolemia were a frequent finding in the RAPA group (Table 1) . SRL treatment was also associated with a significant decrease of the platelet count. Liver enzymes levels were similar in all groups. Arthralgia was only reported in three patients (one male and two females) from the RAPA group. Two cases of impaired glucose tolerance was found in the CsA-1 and CsA-2 groups.
IFNc-producing cells
The number of unstimulated IFNg-producing cells was similar in all groups ( Figure 1 Table 2) .
IL-4-producing cells
As shown in Figure 2, 
Th1/Th2 balance
IFNg-/IL-5-producing cell ratio is shown in Figure 3 . Similar results were observed in all groups of unstimulated cells. After PHA stimulation, the IFNg-/IL-5-producing cell ratio was significantly lower in CsA-1 and CsA-2 groups when compared to CON group (Po0.05), but significantly higher (Po0.05) when compared with the RAPA group ( Figure 4 ).
PBMC production of IL-12 and IL-18
Basal PBMC production of IL-12 was similar in all groups ( PBMC; Po0.01). No differences in IL-18 production were also observed among CsA-1, CsA-2 and RAPA groups.
DISCUSSION
The Th1/Th2 paradigm has evolved as a unifying model to explain the cytokine responses associated with T-cell activation in such different settings as autoimmune disease and tolerance induction. Several studies indicate that a prevalence of Th1 over Th2 characterizes renal allograft rejection, whereas recruitment of Th2 is associated with graft tolerance. 15, 16 These studies suggest that an effective immunosuppressive treatment should be aimed to prevent Th1 activation and maintain an equilibrated balance between Th1 and Th2. As yet, the impact of different immunosuppressive regimens on Th1/Th2 balance has been poorly investigated; in particular we ignore the effects of SRL, a drug that has the major advantage, in comparison with calcineurin inhibitors, of being not nephrotoxic.
Recently, ELISPOT assay has been proposed to study Th1/ Th2 balance in kidney-transplanted recipients. 13, 14 This method allows the detection of cytokines secreted by single cells within a polyclonal population allowing a detailed analysis of lymphocyte populations secreting one or more cytokines. Our data, based on ELISPOT analysis, showed that both SRL-and CsA-based immunosuppressive regimens induce a significant suppression of IFNg-and IL-5-producing cells.
These results confirm that inhibition of Th1 is associated with immunosuppressive treatment aimed to avoid graft rejection, 17, 18 and are consistent with previous cell culture studies showing inhibition of IFNg gene expression in the presence of CsA and SRL. 19, 20 In a heart allograft rat study, SRL also appeared to block significantly IFNg mRNA expression. 20 Our study shows that the number of IFNgproducing cells is lower in patients on SRL-than in patients under CsA-based regimens. These data are consistent with previous animal studies showing that SRL immunosuppression can be 20-100 times more potent than CsA. 18 To our knowledge, the current literature lacks human studies on the effectiveness of SRL on Th subsets. This is the first report showing that SRL inhibition is more effective than CsA in blocking Th1 recruitment in a setting where T cells are activated, that is, reproducing acute rejection. Th2 response measured as number of IL-4-and IL-5-positive cells of PHA or allostimulated PBMC collected from grafted patients was inhibited when compared with normal controls but did not show differences when compared with SRL-or CsA-based immunosuppression. A previous mRNA expression study on human PBMC from normal individuals also showed that either SLR or CsA suppress both IL-4-and IL-5 expression elicited by PHA. 21 Our report shows that SRL inhibition on IFNg is significantly more effective than CsA suggesting a better Th1 blockade in kidney-transplanted patients.
In our work, LPS-stimulated PBMC collected from RAPA patients released less IL-12, but similar amounts of IL-18, when compared with PBMC from both CsA groups. It suggests that IL-12 and IL-18 could differentially amplify CD4 þ T cell production of IFNg. In a previous study, murine carcinoma cells expressing mIL-12 or mIL-18 appeared to be less tumorigenic than control cells and that the antitumor effect required IFNg 22 suggesting a synergistic effect of IL-12 and IL-18 in inducing Th1 polarization of CD4 þ T cells. However, data by Takeda et al. 23 showed that splenic T cells from IL-12 À/À mice did not differentiate into IFNg-producing Th1 cells by in vitro stimulation with IL-18, although in vitro stimulation with IL-12 induced almost normal Th1 cell development in IL-18 À/À mice. Robinson et al. 24 showed that IFNg-inducing factor cannot replace IL-12 but synergizes with IL-12 for IFNg production. Moreover, Seder et al. 25 demonstrated that IL-12 acts directly on CD4 þ T cells enhancing their ability to develop into IFNgproducing cells. These data suggest that IL-12, but not IL-18, could be a relevant cytokine in the CD4 þ microenvironment to polarizing T cells toward the Th1 phenotype.
Downregulation of Th1 cytokine release that we observed in the RAPA group can then be explained not only with a significant monocyte production of IL-12, but also by immature SRL-treated dendritic cells (SRL-DC) migration to lymphoid tissues. SRL-DC inhibit IFNg T-cell production promoting Th2 polarization. In vitro and in vivo data by Sordi et al. 26 demonstrated an increased surface expression of chemokine receptors and lymphoid migratory activity of human and mouse SRL-DC. CsA and tacrolimus instead did not activate either chemokine receptors expression and lymph node migration. 26 Mouse-derived SRL-DC showed reduced IFNg production associated to Janus kinase 2/signal transducer and activator of transcription 4 and their administration significantly prolonged survival of mouse cardiac allografts. 27 Monti et al. 28 found a dose-dependent reduction of IFNg in T cells after SRL-DC stimulation. Finally, Tao et al. 29 described how SRL-DC are resistant to maturation influencing immune reactivity and tolerance induction through downregulation of T-cell alloreactivity.
When peripheral tolerance to allogenic organ grafts occurs, CD4 þ T cells appear to develop the capacity of inducing tolerance in further cohort of T cells. This mechanism of 'infectious tolerance' , maintained by a Th2 polarization or even by a Th2-like activation, is a recent attractive explanation for allogeneic organ transplantation tolerance. 7, 15, 30 Several in vivo studies on cytokine expression during tolerance induction have consistently shown a dramatic decrease of IL-2 and IFNg expression 30 encouraging the hypothesis that polarization toward Th2 might improve graft survival. Our report shows that SRL-based immunosuppression lowering Th1/Th2 ratio results in a more effective Th2 polarization of CD4 þ T cells when compared to CsA-based immunosuppression in kidney-transplanted patients.
Recent works have elucidated clearly the effects of SRL on CD4 þ CD25 þ T cells (Treg). [31] [32] [33] In summary, our findings suggest a sequence of events beginning with inhibition of monocyte activation associated with low release of IL-12. The significantly lower release of IL-12 in patients on SRL-based immunosuppression and SRL-DC-induced T-cell alloreactivity could explain the reduced IFNg-/IL-5-producing cell ratio eventually resulting in a prevalence of Th2 cells in these patients. The present understanding of acute and chronic allograft rejection has identified a cell-mediated mechanism where CD4 þ Th1 cells play a central role, whereas modulation of Th2 response might improve host tolerance 7, 8, 34 and eventually late graft survival. Whether long-term management with SRL improves long-term graft survival reducing the toxic effects of calcineurin inhibition together with a more effective Th1 inhibition should be evaluated in future prospective studies.
MATERIALS AND METHODS Study design
The study was conducted in accordance with the Declaration of Helsinki, and all patients provided written informed consent.
Twenty-four recipients of first cadaveric kidney transplant (13 males and 11 females) were enrolled into the study. At the time of transplant, operation patients were randomly assigned to one of the three immunosuppressive regimens: (1) RAPA group: SRL and mycophenolate mofetil (MMF); (2) CsA-1 group: CsA and MMF; and (3) CsA-2 group: CsA and methylprednisolone (MP). To study clinically stable patients, they were included into the study at third month after kidney transplantation. Blood was always collected from patients just before the assumption of immunosuppressive therapy and after overnight fasting. Within the month previous enrolment and at the time of bleeding, all transplanted patients did not present laboratory or clinical signs of both infection and acute rejection.
Unstimulated and PHA-stimulated T-cell polarization was analyzed measuring IFNg, IL-4, and IL-5-secreting PBMC detected by an ELISPOT assay. The number of IL-5-and IFNg-producing cells of patients and CON group was also measured after allostimulation as we described in a previous paper. 35 In brief, PBMC were isolated from the buffy coat of 10 healthy volunteer donors (Trasfusion Center, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy). Leukocyte-rich buffy coat cells were centrifuged over Ficoll-Hypaque layers to collect PBMC. CD3
þ T cells were depleted by negative selection with anti-CD3 magnetic microbeads (Miltenyi Biotec, Bergisch Gladbach, Germany). PBMC CD3 þ depleted were irradiated at 30 Gy using a g-radiation source, and cocultured with equal numbers of PBMC from kidneytransplanted patients and CON.
IL-12 and IL-18 levels were analyzed in cell-free supernatants obtained from unstimulated and stimulated PBMC.
Intraindividual variability was analyzed in a preliminary study performed on six-transplanted patients and three healthy volunteers. Blood samples were collected in three consecutive days for both ELISPOT and cytokine analysis on cell-free supernatants. Withinsubject ELISPOT variability for both renal-transplanted patients and volunteers was always less than 27, 32, and 30% for IFNg, IL-4, and IL-5, respectively. To avoid the wide citokine variability usually observed on plasma samples, 36 IL-12 and IL-18 levels were analyzed on cell-free supernatants of PBMC cultures. Within-subject variability for both renal-transplanted patients and healthy volunteers for IL-12 and IL-18 was always less than 25 and 33%, respectively.
Patients
RAPA group: Eight patients (three males and five females) aged 46.2712.3 years were treated with SRL in association with MMF (22.975.5 mg/kg/day) and MP (8 mg/day all patients). CsA-1 group: Eight patients (four males and four females) aged 45.879.6 years (P ¼ NS vs RAPA) were treated with CsA and MMF (21.777.5 mg/kg/day; P ¼ NS vs RAPA). CsA-2 group: Eight patients (six males and two females) aged 44.2711.5 years (P ¼ NS vs RAPA and vs CsA-2) treated with CsA, MMF (20.076.6 mg/kg/ day; P ¼ NS vs CsA-1), and MP (16 mg/day all patients). Patients treated with SRL received an oral loading dose of 3.5 mg/m 2 /day for 2 days, followed by 2.5 mg/m 2 /day, then adjusted to achieve steadystate whole-blood trough levels of approximately 12-16 ng/ml (Table 3) . Patients treated with CsA received an initial oral dose of 8 mg/kg/day then adjusted to maintain whole-blood trough levels of 200-300 ng/ml for 2 months, and 200-250 ng/ml thereafter ( Table 3 ). None of the enrolled patients was under treatment with drugs known as immunomodulators, such as statins, calcitriol, and angiotensin-converting enzyme inhibitors, after kidney transplantation. Blood samples were also collected from eight healthy volunteers (CON) aged 38.4710.6 years (four males and four females; P ¼ NS vs all transplanted groups).
Trough-level determinations
Whole-blood SRL levels was monitored using high-performance liquid chromatography (HPLC) with ultraviolet detection. 37 Wholeblood CsA was detected using a monoclonal technique (Abbott TDX, Diamond Diagnostics, Holliston, MA, USA). Plasma total mycophenolic acid levels were measured by reversed-phase highperformance liquid chromatography.
Cell separation PBMC were isolated from peripheral blood by standard Ficoll density-gradient centrifugation and were either used immediately or frozen for later use. 38 Average PBMC lymphocytes and monocytes removed was 77% (range 75-80) and 23% (range 20-25), respectively. Average PBMC lymphocyte fractions harvested from RAPA, CsA-1, and CsA-2 groups were similar among the three groups 79, 77, and 76%, respectively. PBMC viability determined by tryptan blue dye exclusion test was always greater than 95%.
PBMC cultures
PBMC were resuspended at a cell density of 2 Â 10 6 cells/ml in Rosewell Park Memorial Institute 1640 medium (Invitrogen, Carlsbad, CA, USA) containing 1% decomplementated fetal calf serum inactivated at 561C (Sigma-Aldrich, St Louis, MO, USA) in humidified atmosphere containing 5% CO 2 , 2mM L-glutamine, 100 IU/ml penicillin, and 100 g/ml streptomycin (Sigma-Aldrich). Unstimulated or tested against LPS (10 mg/ml; Sigma-Aldrich, Milan, Italy) PBMC were cultured for 24 h and analyzed. Cell-free supernatants were collected by centrifugation for 10 min at 400 r.p.m., passed through a millipore filter (0.2 m, Sigma-Aldrich) and stored at À801C.
39
ELISPOT assay Th1 and Th2 cell function was evaluated by measuring PBMC production of IFNg and IL-5 by the ELISPOT assay as described previously. 40 Briefly, 96-well plates (Polyfiltronics, Rockland, MA, USA) were coated with 100 ml capture monoclonal antibodies (MoAb) specific for IFNg (clone 2G1, 5 mg/ml, Endogen, Woburn, MA, USA) or IL-5 (clone 5A10, 8 mg/ml, Endogen) in phosphatebuffered saline (PBS) overnight at 41C. Plates were washed and blocked for 2 h at room temperature in 10% fetal calf serum phosphate-buffered saline, then 3 Â 10 5 PBMC were resuspended in 100 ml Rosewell Park Memorial Institute medium. Unstimulated, PHA stimulated (15 ml/ml), or antigen-presenting cells allostimulated plates were incubated for 48 h at 371C, washed and wells coated with 100 ml IFNg MoAb (clone B133.5 1 mg/ml, Endogen) and IL-5 MoAb (clone 39D10, 2 mg/ml, Endogen) for 2 h at 371C. After washing, all wells were coated with 100 ml of HRP-conjugated streptavidin (Endogen), incubated for 30 min, washed again and developed using a 3-amino-9-ethylcarbazole (Sigma-Aldrich) filtered solution obtained diluting 1 mg into 30 ml of 0.1 mol/l sodium acetate buffer mixed with 15 ml H 2 O 2 .
IL-4 were measured by commercial ELISPOT assay (Quantikine, R&D System, Minneapolis, MN, USA) performed on microtiter plate.
Spots were counted with an automated ELISA-Spot Assay Video Analysis System (A-EL-VIS, Hannover, Germany). Results were expressed as number of spots/2 Â 10 5 seeded cells. 
